NCT00452218View on ClinicalTrials.gov

Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Sorafenib

200 mg daily and dose escalated to a maximum of 400 mg twice daily

Trial Locations (1)

60637

The University of Chicago, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

University of Chicago

OTHER

NCT00452218 - Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) | Biotech Hunter | Biotech Hunter